Pope Leo XIV had minimally invasive surgery to remove a lung adenocarcinoma at Rome's Gemelli Hospital, with the procedure completed without complications. The tumor was found during a routine exam and described as early-stage, though official pathologic staging is still pending. The final pathology report will determine whether additional treatment — such as targeted therapy, immunotherapy, or chemotherapy — is needed.
Pope Leo XIV underwent a video-assisted lobectomy at Rome's Gemelli Hospital to remove a lung adenocarcinoma — a type of non-small cell lung cancer (NSCLC) — discovered during a routine examination. The roughly 90-minute procedure removed the lower lobe of his right lung with curative intent and was completed without complications. Intraoperative histology confirmed the adenocarcinoma diagnosis, and the Vatican described the resection as "radical," meaning all suspicious tissue was removed.
The critical next step is the final pathology report, expected within days, which will establish the official TNM stage, confirm clear resection margins, and assess lymph node involvement. If the cancer is early-stage with no high-risk features, structured surveillance may be all that's needed. However, if higher-stage disease, actionable mutations (e.g., EGFR, ALK), or adverse histologic features are found, additional therapies — including osimertinib, alectinib, atezolizumab, pembrolizumab, or platinum-based chemotherapy — could be considered.
Key Takeaways:
Why it matters: This case offers a real-world clinical lens on early-stage lung cancer management — from surgical approach to post-op decision-making — at a moment of high public interest, underscoring the importance of routine screening and timely intervention.
